Lv55
1190 积分 2023-12-04 加入
Nonclinical Drug Administration
2小时前
已完结
Session 5: Protein Degraders
3小时前
已完结
Developing early formulations: Practice and perspective
3天前
已完结
Distinct phases of cellular signaling revealed by time-resolved protein synthesis
10天前
已完结
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
22天前
已完结
A new BRAF inhibitor breaks resistance barriers
23天前
已完结
Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development
23天前
已完结
[Preliminary studies on the role of mast cells in the phenotype and immune activation of type 2 inflammatory cytokine release of atopic dermatitis]
29天前
已完结
Establishment of a mouse model for immunological contact urticaria
29天前
已完结
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
29天前
已完结
小干扰RNA药物在慢性病领域的研究新进展：从临床前到临床
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
皖公网安备34019202002308
